A market-focused report revisited the FDA approval of Revolution Medicines’ oral pancreatic cancer therapy Rasonque (daraxonrasib) and how investors interpreted the move. Despite the Priority Review and Breakthrough Therapy/Orphan Drug designations, the stock initially stayed flat, reflecting disagreement over pricing and near-term sales expectations. The piece also contextualized how the Phase III RASolute 302 Phase III results previously drove a sharp market reaction when disclosed. For biotech investors and commercial strategists, the episode emphasizes that regulatory milestones may not translate directly into immediate equity momentum without clarity on uptake, net pricing, and reimbursement trajectory.